Erosive arthritis (EA) in systemic lupus erythematosus (SLE) can be debilitating and deforming with uncertain factors for risk, although antibodies to the A2 hnRNP core protein, known as anti-RA33, have been associated with EA. Two hundred patients under long-term follow-up for SLE were evaluated for EA and associated clinical and serological abnormalities. In addition, sera were tested in a masked fashion for anti-RA33 antibodies in a total of 60 patients: 10 with EA and 50 age-, sexand ethnically matched controls. Ten of 200 (5%) patients with SLE, mainly non-white women, had EA. There were trends for increased renal involvement (P = 0.06), Sjö gren's syndrome (P = 0.07) and Raynaud's phenomenon (P = 0.03) in patients with EA compared to those without EA. Rheumatoid factor (RF ) was increased in patients with EA (P < 0.02), as were antibodies to double-stranded DNA (P < 0.05), Sm (P < 0.01) and La/SS-B (P < 0.001). Anti-RA33 antibodies were present in 70% with EA compared to 28% without EA (P < 0.05). RF correlated with anti-RA33 antibodies in patients with EA, but not with the presence of anti-RA33 alone. Thus, anti-RA33 antibodies may identify those patients with SLE who are at risk for EA, and an association with RF suggests a common immune response or pathological mechanism in autoimmune erosive joint disease.
S lupus erythematosus (SLE) is an autobodies may identify patients at risk for developing EA, the following study was undertaken to establish the immune rheumatic disease characterized by a diversity of both clinical and immunological abnormalities.
frequency of anti-RA33 antibodies with EA in patients with SLE in a large group of patients, and the clinical Prominent amongst the immunological abnormalities is the presence of autoantibodies to a somewhat and serological associations of the antibodies, if any. restricted range of self-antigens [1] . There have been many attempts to link particular antibodies to clinical PATIENTS AND METHODS features or subsets of lupus [2] [3] [4] . Thus, it is accepted Patients generally that patients with high anti-double-stranded
The clinical and laboratory data described are on (ds) DNA antibody levels are most likely to have renal the first 200 patients with SLE to be reviewed with a disease, those with anti-Ro antibodies to have photominimum follow-up of 2 yr or until death. Of these sensitive skin rashes, subacute cutaneous lupus or the 200 patients, 24 have now died. Five additional neonatal lupus syndrome, those with anti-U1snRNP patients, none of whom had EA, were followed for to suffer frequently from myositis and Raynaud's phe-<1 yr and were not included in the study. A diagnosis nomenon, and patients with anti-phospholipid antiof SLE was established in all patients by the revised bodies to have arterial/venous thrombosis, recurrent ARA classification criteria [8] . None of the patients miscarriages and livedo reticularis. In an earlier small had drug-induced SLE. All patients with joint pains study of 30 patients with lupus [5] , we proposed that were X-rayed, and erosions were carefully sought. EA there might be a link between antibodies to the A2 was defined by radiographic evidence of EA of the hnRNP core protein, known as anti-RA33, and erosive hands and/or feet on standard views. joint disease in SLE.
Patients were classified into two groups: those with Although joint pain and swelling are common fea-EA (Group 1; n = 10) and those without EA (Group 2; tures of SLE, erosive arthritis ( EA) is reported genern = 190). Involvement of the central nervous system ally in <5% of patients [2] . EA may be debilitating (CNS), heart, lungs, joints and kidneys, as defined by and deforming with uncertain factors for risk, although
Morrow et al. [9] , was recorded for the analysis, non-erosive arthritis in SLE has been associated with as well as secondary Sjö gren's syndrome (SS ) and sicca syndrome [6 ] and a decreased frequency of Raynaud's phenomenon (RP). Renal involvement was concomitant renal disease [7] . Because anti-RA33 antidefined as glomerulonephritis (GN ) on biopsy or with diastolic blood pressure > 90 mmHg, oedema requiring diuretic therapy, proteinuria > 0.5 g/24 h, creatin- by the criteria of Vitali et al. [10] .
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Antibodies to dsDNA were detected by ELISA (Cambridge Life Sciences). The presence of antibodies development of SS or anti-RA33 antibodies in either patients with or without EA (data not shown). to Ro/SS-A, La/SS-B, Sm and RNP was established by ELISA (Shield Diagnostics). Rheumatoid factor
In general, serological tests were significantly increased in patients with EA (Table II ) . Rheumatoid (RF ) was detected by the Rose-Waaler method. These serological tests were carried out in the same factor was more frequent in patients with EA (P < 0.02), as were antibodies to Sm (P < 0.01) and laboratory.
The medical literature from 1983 to the present was La/SS-B (P < 0.001). There was a trend for increased anti-dsDNA antibodies in patients with EA (P < 0.05). reviewed for SLE with EA and SLE with EA and GN.
Antibodies to RNP were not significantly increased in a comparison of the two groups.
RA33 antibody testing
Anti-RA33 antibody testing was performed using Seven of 10 patients (70%) with EA had anti-RA33 antibodies. Of the 50 patients without EA who were immunoblotting with soluble nuclear extracts from HeLa cells as previously described [11] . A total of 60 tested for anti-RA33 antibodies, 30 were Caucasian, 10 were Afro-Caribbean and 10 were Asian. Fourteen sera were tested in a masked fashion. Of these sera, 10 were from the patients with EA in addition to 50 sera of these patients (28%) tested positive for anti-RA33. Thus, antibodies to RA33 were more frequent in from age-, sex-and ethnically matched patients selected from the 190 in Group 2.
patients with EA (P < 0.05). Serological tests were compared among all anti-RA33-positive patients for an association with EA ( Table III ) . Rheumatoid factor Statistical analysis Data were analysed by x2 test using Yates correction, alone was more frequent in those with anti-RA33 and EA (P < 0.05). Among these patients, five had antibodexcept when n < 10, in which case Fisher's exact test was used. A P value of <0.02 was considered statisticies to RA33 and were RF positive, two had antibodies to RA33 but no RF, and one was RF positive without ally significant.
antibodies to RA33. Thus, 80% of the EA patients had RESULTS Erosive arthritis was present in 10 of 200 patients (5% of the total ) and preceded or coincided with the erosive arthritis (EA)* diagnosis of SLE in 8/10. All patients with EA were women, and 50% were non-Caucasian ( Table I ) .
SLE patients SLE patients
In comparison, patients without EA were mainly
Caucasian women, with other ethnic groups comprising 26% of the study group. The duration of disease did not appear to relate to the *Values are the number (%). SLE, systemic lupus erythematosus; RF, rheumatoid factor; dsDNA, double-stranded DNA.
†P value determined by x2 test using Yates correction. anti-RA33 and/or RF, compared to 44% of control patients with EA, while 23/174 (13%) patients tested without EA were DR4 positive. Indeed, the DR4 type patients without EA (anti-RA33 and RF, n = 2; anti-RA33, n = 11; RF, n = 9). Antibodies to dsDNA, Sm, may be decreased in patients with nephritis [16 ] , an unusual feature in RA, but frequent in our patients La/SS-B and RNP appeared to be increased in the anti-RA33-positive patients with EA, but these did not with EA. Thus, it is unlikely that the patients with erosive joint disease had RA as well as SLE. reach statistical significance.
Initially, anti-RA33 antibodies were thought to be DISCUSSION highly specific for RA, but have since been reported in 20-40% of patients with SLE [5, 17] and may Arthralgia rather than arthritis occurs in the majority of patients with SLE. Joint deformities may identify the subset with EA. In the present series, 70% of all patients with EA and SLE had anti-RA33 resemble rheumatoid arthritis (RA) despite few erosions and dominant ligamentous laxity [2] . Erosive antibodies compared to 28% of controls studied. In contrast, antibodies to RA33 have been identified in arthritis is unusual, estimated at <5% of patients [2] . Whereas non-erosive deforming arthritis has been assoonly 35% of patients with RA [17] . That 80% of our patients with EA had anti-RA33, RF, or both, comciated with sicca syndrome and a decreased frequency of facial erythema and photosensitivity [6 ] , risk factors pared to 44% of SLE patients without EA, suggests that anti-RA33 antibodies, like RF, are representative remain uncertain for EA. Clinical impression suggests that concomitant EA and renal involvement is rare markers of erosive disease. Antibodies to RA33 recognize a 33 kDa nuclear despite the considerable frequency of lupus nephritis. Indeed, the presence of serum RF has been implicated antigen that is present in the 40S hnRNP complex and is indistinguishable from the A2 hnRNP core protein as 'protective' against nephritis, though unproven [12] . Furthermore, persistent rheumatoid-like arthritis [18] . Although the physiological role for RA33 is not fully known [17, 18] , the hnRNP core proteins interact rather than RF appears to be inversely correlated with renal abnormalities, based on clinical data or kidney with heterogeneous nuclear RNA and constitute part of the spliceosome, a multimolecular structure which biopsy [7] .
As in most series, EA was unusual among our SLE processes mRNA [19] . Antibodies to other spliceosomal proteins (Sm and RNP) target the small nuclear population, being present in 5% of our patients and tending to occur in non-white women. Although the RNP complex (snRNP) and have been described in SLE, but not in RA. Anti-Sm and anti-RNP have been prevalence of GN in the total SLE population was relatively low (29%), perhaps a result of follow-up in identified in association with anti-RA33 antibodies in a general population of patients with SLE [17] , but a rheumatology clinic rather than a nephrology unit, kidney involvement appeared to be over-represented there was no significant relationship in the present study of either anti-RA33-positive patients with EA or in the EA group compared to the non-EA group. Interestingly, there was a trend for increased SS among in the total anti-RA33-positive population (data not shown). However, since antibodies to the snRNPs as our patients with EA, an association which appears with variable frequency in the MRL/l mouse model of well as to the hnRNPs were much more frequent in SLE patients with EA compared to those without, it SLE and may be due to local RF production or immune complex deposition [13] . must be assumed that the autoimmune response to the spliceosome is related to erosive joint disease in SLE. Although this study was not designed to look at true polyclonal activation and epitope spreading, it is
The presence of RF, however, correlated with antibodies to RA33 in SLE patients with EA, but not with intriguing that our patients with EA appear to have had more widespread or severe disease than those the presence of anti-RA33 alone, perhaps suggestive of a common pathomechanism in erosive joint disease. without EA. The duration of disease, however, did not appear to relate to the development of SS or antiIn summary, anti-RA33 antibodies may define those patients with SLE, mainly non-white women, who are RA33 antibodies in either patients with or without EA, and our data only give an approximate time when at risk for EA as well as renal disease. The presence of anti-RA33 antibodies appears to correlate with RF the joint disease became erosive. Therefore, the relative severity of disease in our patients with EA remains positivity in these patients, but not in a general population of SLE. Moreover, erosive joint disease in SLE, unclear.
With a prevalence similar to RA in the general regardless of anti-RA33 positivity, may correlate with RF in association with particular autoantibodies. population, it has been suggested that EA is not a feature of SLE, but concomitant RA [14] . Although Perhaps future, prospective studies of patients with SLE may clarify the role of these autoantibodies in the distinction between RA/SLE overlap and SLE with EA may be unclear in some cases, all patients with EA the immune response and pathogenesis of autoimmune erosive joint disease. in the present series fulfilled at least four diagnostic criteria for SLE, 8/10 fulfilling Á5. Moreover, our patients with EA tested more frequently for circulating R autoantibodies characteristic for SLE, in particular with RA [15] , this type was present in only one of our
